Business Context and Reporting Period
Company: ARCA biopharma, Inc. (formerly Nuvelo, Inc. following a reverse merger completed on January 27, 2009).
Reporting Period: Quarter and six months ended June 30, 2009.
Business Stage: Development stage biopharmaceutical company focused on genetically-targeted therapies for heart failure.
Lead Asset: Gencaro (bucindolol hydrochloride), a beta-blocker for chronic heart failure. On May 29, 2009, the FDA issued a Complete Response Letter (CRL) stating the New Drug Application (NDA) could not be approved in its current form, requiring additional clinical efficacy trials and studies. This has substantially delayed potential approval.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2009 | Six Months Ended June 30, 2008 |
|---|---|---|
| Revenue | $0 | $0 |
| Total Costs and Expenses | $24,017 | $7,975 |
| Loss from Operations | $(24,017) | $(7,975) |
| Gain on Bargain Purchase | $25,282 | $0 |
| Net Income (Loss) | $1,356 | $(7,841) |
| Net Income (Loss) Attributable to Common Stockholders | $440 | $(7,870) |
| Cash and Cash Equivalents (End of Period) | $19,014 | $6,927 |
| Marketable Securities | $5,026 | $0 |
| Total Current Liabilities | $19,247 | $15,830 |
| Bank Note Payable | $2,993 | $3,948 |
Note: The Net Income for the six months ended June 30, 2009, is primarily driven by a non-cash $25.3 million gain on bargain purchase resulting from the reverse merger with Nuvelo, Inc. Operating cash flow remains negative.
Material Changes vs. Prior Period
- Merger Impact: The company completed a reverse merger with Nuvelo, Inc. in January 2009. This resulted in a significant increase in cash and marketable securities (acquired ~$45.5 million) and a $25.3 million gain on bargain purchase.
- Expense Increases: Total costs and expenses increased by approximately $16 million compared to the prior year period. This includes:
- R&D Expenses: Increased to $8.1 million (from $4.6 million) due to clinical development costs for Nuvelo assets (NU172, NU206) and Gencaro regulatory work.
- SG&A Expenses: Increased to $9.2 million (from $3.4 million) due to integration costs, public company reporting requirements, and facility leases assumed in the merger.
- Merger Transaction Costs: $5.5 million expensed in the current period (none in prior period).
- Restructuring Expense: $1.3 million recorded in Q2 2009 for employee terminations and asset impairments.
- Debt Repayment: Convertible notes payable of $8.4 million outstanding at year-end 2008 were converted to common stock upon the merger closing. A bank note payable of ~$3.0 million remains outstanding.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management states there is substantial doubt about the company's ability to continue as a going concern after December 31, 2009. Current cash is expected to fund operations only through the end of 2009.
- Regulatory Outlook: The FDA CRL requires an additional Phase 3 efficacy trial for Gencaro. Approval is substantially delayed. The company is evaluating strategic alternatives (e.g., licensing, merger) rather than building an internal sales force.
- Restructuring: Implemented in Q2 2009, terminating 44 employees to reduce operating expenses. Expected to yield net cash savings of ~$3.0 million for the remainder of 2009.
- Unusual Items:
- Gain on Bargain Purchase: $25.3 million non-recurring gain recognized due to the merger accounting.
- Facility Exit Costs: Accrued liability of $10.9 million related to a Sunnyvale, CA facility lease assumed in the merger. In August 2009 (subsequent event), the company terminated this lease, expecting a gain of ~$2.3 million in Q3 2009.
- Liquidity Needs: The company will need to raise substantial additional capital or complete a strategic transaction to fund the additional clinical trials required by the FDA and to commercialize Gencaro if approved.
Investor Verification Checklist
- FDA Response Strategy: Verify the specific scope and cost of the additional Phase 3 trial and pharmacology studies required by the FDA's Complete Response Letter.
- Cash Runway: Confirm the timeline for cash depletion and the status of any ongoing fundraising efforts or strategic transaction negotiations.
- Lease Termination Gain: Monitor the Q3 2009 financials for the expected $2.3 million gain from the Sunnyvale facility lease termination.
- Debt Covenants: Review the terms of the remaining bank note payable and any potential covenants that could be triggered by continued losses or cash balance thresholds.
- Intellectual Property: Assess the status of the Gencaro license agreement with CPEC, specifically the $8.0 million milestone payment obligation upon FDA approval.